Dyad Medical Secures FDA Clearance For Echo:Prio™ Cardiac Imaging Analysis Application

Esad Vucic

MD, PhD

Dr. Vucic earned his MD degree from the University of Tuebingen, Germany. He then completed a postdoctoral fellowship at the Department of Physiology at Yale University, New Haven. He then continued with his internship at SUNY Downstate, Brooklyn, New York and residency in internal medicine at Mount Sinai St. Luke’s-Mount Sinai West, New York. Following his training in Internal Medicine, Dr. Vucic performed research training in advanced cardiac imaging focused on Magnetic Resonance Imaging, Computed Tomography and Nuclear imaging at the Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York. He then completed fellowships in Cardiovascular Disease at Mount Sinai Hospital, New York, Advanced Cardiac Imaging at the Massachusetts General Hospital, Boston and Cardiac Electrophysiology at New York University, New York.

He joined Newark Beth Israel, in 2019 and is heading the advanced cardiac imaging service with a focus on cardiac MRI and cardiac CT.

Dyad Medical Secures FDA Clearance For Echo:Prio™ Cardiac Imaging Analysis Application

August 15, 2022

Boston, Massachusetts (August 15, 2022)– Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis, announced that the U.S. Food and Drug Administration (FDA) has cleared its Echocardiogram application called Echo:Prio^TM through the 510(k) pathway. Echo:Prio^TM , part of the complete cardiac platform named Libby®, offers fast, data-driven image analysis of echocardiogram images. It is an important decision-making support tool for index quantification of cardiac function saving the clinician time in diagnosis and treatment-decision making.

Echocardiograms are often the first step in diagnosing and developing a treatment plan for heart disease. The heart is the only organ in constant movement as it pumps blood throughout the body. When analyzing the left ventricle, any abnormal motion may be a sign of heart disease. Most imaging labs rely on visual detections of these abnormalities to diagnose and manage heart disease. This subjective process requires a complete view of the endocardium which is not always available. Furthermore, additional factors influencing image interpretations include operator skill level and variations in heart rates and cardiac loading, all of which may be addressed using automated analysis.

“The current process of manual echocardiographic assessment of myocardial function is time consuming and lacks consistency between readings. The FDA’s clearance of Dyad Medical’s Echo:Prio^TM application allows us to provide operators and physicians an essential computer-assisted tool for echocardiographic analysis. Our solution is proven to be consistent and can be used across all systems, regardless of an operator’s skill level,” said Dr. Ronny Shalev, CEO and co-Founder of Dyad Medical, Inc.

Libby® Echo:Prio™ is embedded in the current workflow of imaging operators, physicians, and researchers. The Libby® platform is cloud-based, offering users a secure way to use it from any location on any device. The AI-powered platform provides users an immediately-available second opinion when diagnosing cardiac images saving them critical time that can be spent with patients.

“Dyad Medical’s Echo:Prio™ application allows physicians to prioritize patient treatments and deliver the life-saving care needed for those who need it most,” said Shalev. “Echocardiogram analysis done manually is time consuming and must be done consistently across all patients and operators. Echo:Prio^TM is expanding the physician’s view so they have greater confidence in their diagnosis leading to greater patient satisfaction and retention.”

This is the second FDA clearance Dyad Medical has received for its Libby® cardiac imaging analysis platform. Dyad Medical’s intravascular optical coherence tomography application is also FDA cleared. Focusing on AI-powered analysis of cardiac images, the company continues to enhance its applications for other imaging modalities. To learn more visit www.dyadmedical.com.

About Dyad Medical

Dyad Medical develops clinical applications using cloud-based artificial intelligence aimed at enabling doctors to interpret medical image content more efficiently from anywhere in the world. It is powered by the expertise of a global community of clinicians who train the model, effectively offering practitioners “thousands of second opinions.” Within the digital diagnostics arena, Dyad Medical’s core focus is on cardiac imaging because more people die as a result of cardiovascular disease than all types of cancer, diabetes, and accidents combined. www. dyadmed.com.

Media Contacts:

Rachael Clifford
10 to 1 Public Relations
rachael@10to1pr.com
480-519-3070

Dyad Medical's SaaS based AI for cardiac imaging fundraising exceeds $3.5MM

October 1, 2020

BOSTON, Oct. 1, 2020 /PRNewswire/ — Dyad Medical, Inc., a groundbreaking medical image analysis platform delivering cloud-based artificial intelligence (AI)-based analysis, announced after just 90 days, the closing of its oversubscribed Series Seed funding round led by The Unofficial Syndicate, with participation by Social Starts L.P., and local angel investors. Along with grants from the NIH, this brings Dyad’s total funding to more than $3.5MM.

Dyad, a recent Mass Challenge grad, will use the funding to enhance its patent-pending cardiac imaging software, to accelerate its FDA clearance path and expand their team to prepare for customer deployments. Dyad’s cloud-native platform increases the accuracy and efficiency of cardiac image analysis providing cardiologist and clinicians with near real-time observations that, prior to Dyad, in many cases were invisible to the human eye and time consuming to detail.

“We are the only solution that provides cardiologists with insights on every scan they perform, regardless of the modality used and what part of the heart they scan,” says Dr. Ronny Shalev, co-founder and CEO of Dyad Medical. “We are clear on our goal to provide universal access to expert-level observations by teaching computers to automatically analyze medical images. The Dyad platform, will provide instantaneous cardiac image interpretations globally via the web, accessible by any device, which for a clinician is like having 1000’s of expert second opinions for them to consider in their diagnoses – all in real-time.”

“The combination of artificial intelligence, a brain trust of distinguished scientific advisors, and a cloud-based solution that delivers the only four modality cardiac analysis in the market is game changing. We believe this will become the gold standard in cardiac care and we are excited to help them bring this technology to market,” said Jayme Fishman, Co-founder of The Unofficial Syndicate. “My co-founder, Harry Scott, brought this deal to our consortium and will lead Dyad’s Advisory board as we help them move to commercialization.”

“We believe Dyad will transform the cardiac imaging field by placing cutting-edge technology within cardiologists’ current workflow to efficiently drive faster and more accurate diagnoses,” said Emi Gonzalez, Principal at Social Starts.

About Dyad Medical
Dyad Medical develops clinical applications using cloud-based artificial intelligence aimed at enabling doctors to more efficiently interpret medical image content from anywhere in the world. It is powered by the expertise of a global community of clinicians who train the model, effectively offering practitioners “thousands of second opinions” in real-time. Within the digital diagnostics arena, Dyad Medical’s core focus is on cardiac imaging because more people die as a result of cardiovascular disease than all types of cancer, diabetes, and accidents combined.

About The Unofficial Syndicate
Irreverently named The Unofficial Syndicate is an active angel investment group of “non-members” known for high touch, thoughtful analysis and speed of decision making in finding and nurturing Seed stage companies navigate their formative years. www.TheUnofficialSyndicate.com

About Social Starts
Social Starts is a venture capital partnership with a uniquely data-driven approach to investing in moment-of-inception and Series A financing rounds. Focusing on companies that leverage social and mobile technologies with a particular emphasis on the emerging science and technology of health and happiness www.SocialStarts.com.

Dyad Medical Joins the Qualcomm ‘XR Enterprise Program’

November 14, 2019

Boston, Massachusetts—Nov. 14, 2019—Dyad Medical, a leading provider of deep learning medical image analysis software, announced that it has joined the new Qualcomm® XR Enterprise Program (XEP). The new program allows enterprise solution providers to be part of a global community that offers access to technical support resources, promotional opportunities, co-marketing, joint planning and business development and matchmaking with other members for the collective goal of accelerating the enterprise XR segment to help increase operational efficiencies, worker satisfaction & safety and impact the bottom line.

Dyad Medical develops cardiac medical image interpretation software platform. Dyad Medical’s technology incorporates artificial intelligence to investigate image content and combines it with state-of-the-art visualization technologies to visualize analysis results, guide the clinicians and support diagnostic decision making.

“We’re thrilled to join the exceptional list of startups in the XR Enterprise program, which supports our vision of streamlining patient treatment, reducing diagnostic error rates and making image analysis more accessible,” said Ronny Shalev, PhD, cofounder and CEO of Dyad Medical. “Joining the program will help support our goal for expansion into new markets and help ensure our AI offering continues to be ahead of the curve.”

About Dyad Medical

Dyad Medical is a pioneer in the development of deep learning architectures enabling quick and accurate medical image analysis and interpretation. With a platform developed by data scientists, machine learning practitioners, and medical experts, Dyad Medical is researching and developing analysis algorithms of heart images generated by a variety of data sources improving diagnostic accuracy.

About Qualcomm

Qualcomm invents breakthrough technologies that transform how the world computes, connects and communicates. When we connected the phone to the Internet, the mobile revolution was born. Today, our inventions are the foundation for life-changing products, experiences, and industries. As we lead the world to 5G, we envision this next big change in cellular technology spurring a new era of intelligent, connected devices and enabling new opportunities in connected cars, remote delivery of health care services, and the IoT — including smart cities, smart homes, and wearables. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, all of our engineering, research and development functions, and all of our products and services businesses, including, the QCT semiconductor business. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.

Qualcomm and Snapdragon are trademarks of Qualcomm Incorporated, registered in the United States and other countries.

Qualcomm Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries. The Qualcomm Advantage Network is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.

Find out more at www.dyadmed.com and follow us on Twitter and LinkedIn.

Contact about this news:

Dyad Medical, Inc.
Ronny Shalev, PhD
email: info@dyadmed.com
phone: 617-480-9569

Dyad Medical Joins NVIDIA Inception Program

June 14, 2019

Boston, Massachusetts—June 14, 2019—Dyad Medical, a deep learning medical image analytics company, announced that it has joined the NVIDIA Inception program, which is designed to nurture startups revolutionizing industries with advancements in AI and data science.

Dyad Medical develops clinical applications using artificial intelligence, aimed at enabling doctors to more efficiently and effectively interpret medical image content. Dyad Medical’s solutions will be offered in two spaces:

Research: where image interpretation is done off-line, post-image-acquisition.
In the clinic: to support treatment decision making. Inclusion in the NVIDIA Inception program will provide Dyad Medical with access to
leading-edge resources in artificial intelligence, deep learning and data science, enabling Dyad Medical to strengthen its deep learning expertise.

Dyad Medical will also benefit from access to hardware grants, best-in-class training and more.

“We’re thrilled to join the exceptional list of startups in the NVIDIA Inception program, which supports our vision of streamlining medical image analysis and interpretation, reducing error rates and making image analysis more accessible,” said Ronny Shalev, cofounder and CEO of Dyad Medical. “Joining the program will help support our goal for expansion into new markets and help ensure our AI offering continues to be ahead of the curve.”

NVIDIA’s Inception program is a virtual accelerator program that helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, from hardware grants and marketing support to training with deep learning experts.

About Dyad Medical

Dyad Medical is a pioneer in the development of deep learning architectures enabling quick and accurate medical image analysis and interpretation. With a platform developed by data scientists, machine learning practitioners, and medical experts, Dyad Medical is researching and developing analysis algorithms of images generated by a variety of data sources improving diagnostic accuracy. Dyad Medical was recently selected to participate in the 2019 MassChallenge Boston accelerator program representing the top 9% of applications from around the world, including 61 countries and 25 U.S. states. Find out more at www.dyadmed.com and follow us on Twitter and Linkedin.

Contact about this news:

Dyad Medical, Inc.
Ronny Shalev, PhD
e-mail: info@dyadmed.com
phone: 617-480-9569

Dyad Medical Selected for MassChallenge Boston 2019 Accelerator

May 15, 2019

Dyad Medical joins global network of startups

Boston, Massachusetts, May 15, 2019 – Dyad Medical, deep learning imaging analytics company, today announced that it was selected to participate in the 2019 MassChallenge Boston accelerator program. Rigorously selected by a community of close to 200 expert judges, Dyad Medical represents the top 9% of applications from around the world, including 61 countries and 25 U.S. states.

Through a global network of zero-equity accelerators, MassChallenge identifies the world’s highest-impact, highest-potential startups and helps them successfully launch and grow. As part of the 2019 cohort, Dyad Medical will have unrivaled access to expert mentorship, top corporate partners, and more than 20,000 square-feet of co-working space – all at zero cost and for zero equity. Dyad Medical will also engage in evidence-based curriculum, which has been designed to address key challenges throughout each phase of the early-stage lifecycle, including discovery, development, deployment, and distribution. At the close of the program, startups will compete for more than $1M in cash prizes at the 2019 MassChallenge Boston Awards held on October 24.

“We are on a mission to provide a cardiologist an insight with every single scan they perform, regardless of the modality used and what part of the heart they scan,” says Dr. Ronny Shalev, co-founder and CEO of Dyad Medical. “While we are clear on our goal to provide universal access to expert-level diagnosis by teaching computers to automatically analyze medical images, we are grateful that others understand where we’re going and believe in our mission. Our thanks to MassChallenge for supporting us!”

About Dyad Medical

Dyad Medical develops clinical applications using artificial intelligence aimed at enabling doctors to more efficiently and effectively interpret medical image content. Within the digital diagnostics arena, Dyad Medical’s core focus is in Cardiovascular (more people die as a result of cardiovascular disease than all types of cancer combined) and Neuroradiology image analytics. Dyad Medical’s solutions will be offered in two spaces:

Research: where image interpretation is done off-line, post-image-acquisition.
In the clinic, to support treatment decisions.

About MassChallenge

MassChallenge is a global network of zero-equity startup accelerators. Headquartered in the United States with locations in Boston, Israel, Mexico, Rhode Island, Switzerland, and Texas, MassChallenge is committed to strengthening the global innovation ecosystem by supporting high-potential startups across all industries, from anywhere in the world. To date, more than 1,900 MassChallenge alumni have raised more than $4 billion in funding, generated more than $2.5 billion in revenue, and created more than 120,000 total jobs.